835 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 595 2595
https://www.atreca.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 90
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. John A. Orwin M.B.A. | President, CEO, Director & Principal Financial Officer | 927.03k | N/A | 1965 |
Dr. Tito A. Serafini Ph.D. | Founder & Director | 665.5k | N/A | 1963 |
Mr. Rick Ruiz | Principal Accounting Officer | N/A | N/A | 1964 |
Ms. Courtney J. Phillips J.D. | General Counsel & Corporate Secretary | N/A | N/A | 1975 |
Roger Richard Ruiz | Vice President of Finance | N/A | N/A | N/A |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
Atreca, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 10; Compensation: 10.